TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Oncology Institute ( (TOI) ) is now available.
On November 3, 2025, The Oncology Institute, Inc. announced a cybersecurity incident involving an IT software provider that could delay fee-for-service collections. The delay is expected to be brief and immaterial, with no evidence of compromised patient information. The company is working with the provider to mitigate the impact and restore normal billing operations.
The most recent analyst rating on (TOI) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Oncology Institute stock, see the TOI Stock Forecast page.
Spark’s Take on TOI Stock
According to Spark, TipRanks’ AI Analyst, TOI is a Neutral.
The Oncology Institute’s stock score is primarily impacted by its financial performance, which is weak due to high leverage and negative equity. However, the positive outlook from the earnings call, with strong revenue growth and strategic initiatives, provides some optimism. Technical indicators show moderate momentum, but the valuation remains unattractive due to ongoing losses.
To see Spark’s full report on TOI stock, click here.
More about Oncology Institute
The Oncology Institute, Inc. operates in the healthcare industry, focusing on providing oncology services. The company is involved in the fee-for-service segment, which is a significant part of its operations.
Average Trading Volume: 1,855,918
Technical Sentiment Signal: Buy
Current Market Cap: $396.5M
For detailed information about TOI stock, go to TipRanks’ Stock Analysis page.